<p>Factors Prognostic for Peritoneal Metastases from Colorectal Cancer Treated with Surgery</p>

Abstract

Purpose To analysis factors prognostic for peritoneal metastases (PM) from colorectal cancer (CRC) treated with surgery using data from two sources and investigate the origin and effective treatment of ovarian metastases (OM). Patients and Methods Data from CRC patients with PM who had undergone surgery were collected from the Surveillance, Epidemiology, and End Results (SEER) database (n = 639) and a single Chinese institution (n = 60). Cumulative survival was evaluated by Kaplan–Meier analysis. Factors associated with overall survival (OS) and progression-free survival (PFS) prognosis were assessed using Cox’s proportional hazard regression models. Results Median OS values for patients who underwent surgery were 19 and 32 months in the SEER database and Chinese center, respectively. Age was an independent predictor of OS in both datasets. Signet-ring cell cancer and perineural invasion were independent predictors of inferior OS only in the SEER dataset, while completeness of cytoreduction (CC) and peritoneal carcinomatosis index were independent predictors for OS and PFS only in the Chinese center. Median OS was 24 months in CRC patients with PM alone and 36 months in those with both PM and OM (p = 0.181). Further, median PSF in patients with PM alone was 10 months, while that in individuals with both PM and OM was 20 months (p = 0.181). Conclusion Surgical treatment of the primary and metastatic sites is effective and safe for CRC patients with PM. CC-0 is recommended for improved prognosis. Moreover, OM should be recognized as a feature of PM, and cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy is beneficial for CRC patients with OM.

Treatment and prognosis of colorectal cancer with synchronous peritoneal metastases: 11-year single institute experience

“…Previous studies from China have investigated the association between treatment strategies and OS in patients with colorectal SPM. [20][21][22][23] However, their clinical significance was limited due to the small number of patients investigated, [20][21][22][23] involving metachronous peritoneal metastases, 20 involving appendiceal tumours 22 or patients being treated only CRS plus HIPEC. 23 Although numerous international multicentre cohort studies have been conducted on patients with colorectal SPM, they mainly focused on the benefits of CRS plus HIPEC or primary tumour resection.…”

Comparative Study of Short-Term Efficacy and Safety of Mitomycin versus Lobaplatin for Hyperthermic Intraperitoneal Chemotherapy after Radical Surgery in Colorectal Cancer with High-Risk Factors for Peritoneal Carcinomatosis: A Propensity Score Matching Analysis

“…There are several reports confirming that hyperthermic intraperitoneal chemotherapy (HIPEC) can clear and kill free cancer cells in the peritoneal cavity, which can be used as an effective adjuvant treatment for preventing peritoneal metastasis after surgery of advanced peritoneal tumor [3][4][5][6][7]. There were studies [8][9][10][11][12] that reported that advanced stage, tumor perforation, completeness of cytoreduction, histologic type, tumor location, and nodal stage associated with peritoneal metastasis from CRC. Patients with T4 CRC have a 3-year disease-free survival (DFS) rate of only 58% to 72% after curative surgery and regular adjuvant therapy [13,14].…”